Trial Profile
A study comparing ranibizumab or aflibercept in Neovascular Age-related macular degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Apr 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 16 Apr 2018 New trial record